SONN - Sonnet BioTherapeutics Holdings Inc Stock Price, Fair Value and News

1.82USD-0.03 (-1.62%)Market Closed

Market Summary

USD1.82-0.03

Market Closed

-1.62%

SONN Stock Price

View Fullscreen

SONN RSI Chart

SONN Valuation

Market Cap

5.7M

Price/Earnings (Trailing)

-0.67

Price/Sales (Trailing)

61.09

EV/EBITDA

-0.33

Price/Free Cashflow

-0.43

SONN Price/Sales (Trailing)

SONN Profitability

EBT Margin

-18586.59%

Return on Equity

-275.89%

Return on Assets

-142.6%

Free Cashflow Yield

-231.25%

SONN Fundamentals

SONN Revenue

Revenue (TTM)

92.7K

Rev. Growth (Yr)

-50%

Rev. Growth (Qtr)

-50%

SONN Earnings

Earnings (TTM)

-8.4M

Earnings Growth (Yr)

106.45%

Earnings Growth (Qtr)

131.27%

Breaking Down SONN Revenue

Last 7 days

7.1%

Last 30 days

7.1%

Last 90 days

12.4%

Trailing 12 Months

-71.4%

How does SONN drawdown profile look like?

SONN Financial Health

Current Ratio

1.89

Debt/Equity

0.98

Debt/Cashflow

-4.37

SONN Investor Care

Shares Dilution (1Y)

149.19%

Diluted EPS (TTM)

2.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	92.7K	0	0	0
2023	198.5K	173.3K	147.8K	129.2K
2022	416.8K	383.4K	349.9K	257.4K
2021	0	0	483.6K	450.2K
2020	24.4M	28.7M	0	0
2019	28.6M	28.9M	28.4M	30.9M
2018	41.6M	41.2M	40.6M	30.7M
2017	41.6M	41.4M	41.1M	41.4M
2016	37.9M	40.2M	41.9M	41.8M
2015	29.8M	32.0M	34.2M	36.4M
2014	12.2M	17.4M	25.4M	27.6M
2013	7.1M	7.1M	6.9M	8.2M
2012	3.0M	4.6M	5.9M	6.9M
2011	549.3K	858.4K	1.2M	1.5M
2010	0	447.4K	291.9K	136.3K
2009	0	0	0	603.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sonnet BioTherapeutics Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 27, 2023	mohan pankaj	bought	-	-	34,375	chairman, president and ceo
Oct 27, 2023	rao raghu	bought	-	-	15,625	-
Jun 14, 2023	dexter susan	bought	7,000	0.7	10,000	chief technical officer
May 30, 2023	dyrness albert d.	bought	10,883	0.468	23,255	-
May 17, 2023	bhatt nailesh	bought	5,800	0.232	25,000	-
May 15, 2023	mohan pankaj	bought	82,866	0.223	371,600	chairman, president and ceo
Mar 15, 2023	mohan pankaj	bought	35,100	0.585	60,000	chairman, president and ceo
Feb 06, 2023	griffith donald j.	sold (taxes)	-518	1.043	-497	-
Feb 06, 2023	cross john harry iii	sold (taxes)	-2,077	1.06	-1,960	chief financial officer
Jan 07, 2023	cini john k.	back to issuer	-	-	-18,551	chief scientific officer

Which funds bought or sold SONN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	reduced	-90.16	-95.00	11.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	11.00	11.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	30.04	1,421	5,065	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-51,238	-	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	sold off	-100	-76,000	-	-%
May 10, 2024	BlackRock Inc.	reduced	-12.46	-67.00	967	-%
May 10, 2024	CITIGROUP INC	new	-	71.00	71.00	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	4.76	4.00	41.00	-%
May 10, 2024	OSAIC HOLDINGS, INC.	sold off	-100	-78.00	-	-%
May 10, 2024	VANGUARD GROUP INC	unchanged	-	1,767	27,390	-%

Are Funds Buying or Selling SONN?

Are funds buying SONN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SONN

No. of Funds

Unveiling Sonnet BioTherapeutics Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 02, 2024	markey john	6.5%	198,300	SC 13G/A
Nov 17, 2023	markey john	7.6%	231,115	SC 13G/A
Nov 06, 2023	markey john	6.4%	195,780	SC 13G/A
Aug 07, 2023	markey john	10.7%	4,100,000	SC 13G/A
Jul 17, 2023	markey john	11.1%	3,700,000	SC 13G/A
Jul 07, 2023	markey john	9.9%	3,305,000	SC 13G/A
Jun 30, 2023	markey john	8.5%	2,830,000	SC 13G
Jun 22, 2023	ruck matthew j	6.18%	1,700,000	SC 13G/A
Jun 14, 2023	ruck matthew j	5.83%	1,603,006	SC 13G/A
Jun 14, 2023	ruck matthew j	5.83%	1,603,006	SC 13G/A

Recent SEC filings of Sonnet BioTherapeutics Holdings Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	424B3	Prospectus Filed
May 16, 2024	EFFECT	EFFECT
May 15, 2024	S-1/A	Initial Public Offering
May 14, 2024	8-K	Current Report
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 03, 2024	S-1	Initial Public Offering
May 03, 2024	8-K	Current Report
Mar 11, 2024	8-K	Current Report
Mar 06, 2024	8-K	Current Report

Peers (Alternatives to Sonnet BioTherapeutics Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Sonnet BioTherapeutics Holdings Inc News

Latest updates

Sonnet BioTherapeutics Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	-100.0%	-	18,626	37,255	36,850	36,445	37,255	62,753	62,071	95,320	5,063,547	10,031,773	15,000,000	1,355,000	2,715,030	9,653,440	10,710,773	7,837,588	239,633	10,098,400	10,399,924	9,995,516
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	7,035,328	7,920,004	13,886,882	13,695,319	9,532,462	2,136,460	10,769,716	10,820,269	12,376,357
Operating Expenses	198.2%	3,868,561	1,297,497	3,637,400	3,952,160	5,701,213	5,649,649	7,439,718	7,929,297	8,305,536	6,344,751	7,430,510	-	3,625,844	1,199,435	5,858,495	6,557,415	5,151,483	1,415,944	5,781,284	5,640,614	5,586,149
S&GA Expenses	-100.0%	-	653,455	1,794,765	1,542,689	1,884,569	1,903,709	2,315,790	2,280,345	1,900,263	2,078,885	2,392,208	2,484,148	1,208,374	1,060,906	1,572,774	1,012,290	1,338,881	454,534	1,092,529	1,121,666	1,193,417
R&D Expenses	236.5%	2,167,288	644,042	1,842,635	2,409,471	3,816,644	3,745,940	5,123,929	5,648,952	6,405,273	4,265,866	5,038,302	2,455,822	1,302,515	1,408,148	-	391,914	-	-	-	-	-
EBITDA Margin	-39.3%	-181	-130	-113	-97.11	-84.78	-65.39	-48.09	-43.90	-40.38	-37.38	-34.80	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-3,798	162,988	222,899	162,845	-11,855	208,223	654,274	630,223	629,858	635,081
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,676	12,513	4,803	5,829	50,581	78,137	-206,366	-236,798	-336,197
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,796,202	-7,823,008	-4,286,482	-3,329,837	-1,922,528	-2,485,933	-1,524,978	-1,042,598	-3,018,036
EBT Margin	-39.3%	-185	-133	-116	-99.45	-86.82	-66.96	-49.25	-44.96	-41.35	-38.28	-35.64	-	-	-	-	-	-	-	-	-	-
Net Income	131.3%	365,425	-1,168,509	-3,676,739	-3,946,742	-5,667,071	-5,542,142	-7,435,341	-7,877,020	-8,208,499	-6,200,981	-6,952,073	-11,779,050	-2,496,747	-2,469,054	-4,291,285	-1,416,059	-283,680	-292,047	-1,318,612	-805,805	-
Net Income Margin	18.8%	-90.87	-111	-127	-130	-133	-112	-84.93	-76.27	-65.93	-56.21	-51.66	-	-	-	-	-	-	-	-	-	-
Free Cashflow	123.4%	723,792	-3,091,737	-4,559,113	-6,172,025	-4,695,534	-5,915,170	-6,247,934	-7,824,682	-5,608,563	-8,092,349	-5,938,127	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	10.7%	5,909	5,338	5,429	10,035	13,311	4,943	5,830	7,490	15,046	20,741	28,994	7,176	7,626	3,033	7,994	3,881	31,319	31,533	38,478	45,424	48,086
Current Assets	13.0%	5,223	4,624	4,738	9,633	13,046	4,598	5,414	7,169	14,916	20,584	28,812	6,972	7,398	2,699	7,638	3,502	1,818	1,170	40.00	1,769	1,703
Cash Equivalents	-100.0%	-	3,021	2,274	7,000	11,400	1,700	3,053	5,225	13,636	19,400	27,622	6,038	6,739	2,348	7,350	3,107	549	501	36.00	579	562
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	272	287	354	421	425
Net PPE	-10.6%	27.00	30.00	33.00	37.00	40.00	43.00	46.00	49.00	53.00	56.00	59.00	59.00	62.00	65.00	68.00	71.00	5,325	5,630	8,160	9,012	10,157
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,513	8,568	10,499	11,275	11,313
Liabilities	3.2%	2,855	2,765	5,655	6,616	7,943	8,480	8,369	6,725	6,513	4,350	6,734	5,807	5,603	5,520	4,974	3,501	34,274	34,685	36,592	38,500	41,123
Current Liabilities	4.2%	2,765	2,654	5,525	6,466	7,774	8,293	8,165	6,505	6,513	4,345	6,703	5,752	5,398	5,292	4,724	3,230	18,205	18,095	2,885	19,880	21,975
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,348	6,631	6,682	6,620	6,772
Shareholder's Equity	18.7%	3,054	2,572	-225	3,418	5,369	-3,537	-2,538	764	8,533	16,391	22,260	1,369	2,022	-	3,020	380	-	-	5,133	6,924	6,963
Retained Earnings	0.3%	-111,046	-111,412	-110,243	-106,567	-102,620	-96,953	-91,411	-83,975	-76,098	-67,890	-61,689	-54,737	-48,621	-42,582	-36,705	-29,184	-77,343	-75,068	-12,440	-62,270	-59,025
Additional Paid-In Capital	0.1%	114,101	113,984	110,018	109,982	107,987	93,415	88,872	84,734	84,626	84,275	83,949	56,103	50,642	40,094	39,724	29,564	73,471	71,506	9,594	71,210	65,126
Shares Outstanding	1.4%	3,112	3,070	1,750	1,745	932	314	252	197	196	196	196	73.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	585	456	485	910	1,027
Float	-	-	-	-	-	7,300	-	-	-	22,100	-	-	-	45,019	-	-	-	5,713	-	-	4,300	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	123.4%	724	-3,091	-4,559	-6,172	-4,695	-5,915	-6,247	-7,824	-5,608	-8,092	-5,938	-5,844	-5,787	-4,981	-5,542	-6,439	-1,905	-1,807	-1,770	293	-646
Share Based Compensation	20.8%	60.00	50.00	50.00	50.00	57.00	92.00	86.00	108	351	332	318	318	370	370	-	-	28.00	9.00	7.00	10.00	101
Cashflow From Investing	-	-	-	-170	-12.00	-	-	62.00	-586	-165	-120	-	-	-	-	-	-22.82	-19.71	-21.75	2,930	-183	-18.79
Cashflow From Financing	-98.9%	41.00	3,839	-17.70	1,815	14,646	4,563	-	-	-	-	27,526	5,144	10,178	-20.12	9,786	8,947	2,007	2,684	244	-92.95	597

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SONN Income Statement

2024-03-31

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue		$ 36,445	$ 18,626	$ 73,700
Operating expenses:
Research and development	2,167,288	3,816,644	2,811,330	7,562,584
General and administrative	1,701,273	1,884,569	2,354,728	3,788,278
Total operating expenses	3,868,561	5,701,213	5,166,058	11,350,862
Loss from operations	(3,868,561)	(5,664,768)	(5,147,432)	(11,277,162)
Other income	4,327,946		4,327,946
Foreign exchange (loss) gain	(93,960)	(2,303)	16,402	67,949
Net income (loss)	$ 365,425	$ (5,667,071)	$ (803,084)	$ (11,209,213)
Per share information:
Net income (loss) per share, basic	$ 0.08	$ (7.55)	$ (0.19)	$ (21.14)
Weighted average shares outstanding, basic	4,617,665	750,582	4,205,469	530,131
Net income (loss) per share, diluted	$ 0.07	$ (7.55)	$ (0.19)	$ (21.14)
Weighted average shares outstanding, diluted	4,885,845	750,582	4,205,469	530,131

SONN Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Current assets:
Cash	$ 3,786,184	$ 2,274,259
Prepaid expenses and other current assets	1,058,836	1,677,396
Incentive tax receivable	377,962	786,574
Total current assets	5,222,982	4,738,229
Property and equipment, net	26,944	33,366
Operating lease right-of-use asset	159,641	193,689
Deferred offering costs	15,000	49,988
Other assets	484,842	414,206
Total assets	5,909,409	5,429,478
Current liabilities:
Accounts payable	1,752,444	2,201,999
Accrued expenses and other current liabilities	933,747	3,230,922
Current portion of operating lease liability	78,493	73,048
Deferred income		18,626
Total current liabilities	2,764,684	5,524,595
Operating lease liability, net of current portion	90,446	130,863
Total liabilities	2,855,130	5,655,458
Commitments and contingencies (Note 4)
Stockholders’ equity (deficit):
Common stock, $0.0001 par value: 125,000,000 shares authorized; 3,112,401 and 1,750,426 issued and outstanding at March 31, 2024 and September 30, 2023, respectively	311	175
Additional paid-in capital	114,100,805	110,017,598
Accumulated deficit	(111,046,837)	(110,243,753)
Total stockholders’ equity (deficit)	3,054,279	(225,980)
Total liabilities and stockholders’ equity (deficit)	$ 5,909,409	$ 5,429,478

About Sonnet BioTherapeutics Holdings Inc

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

CEO	Dr. Pankaj Mohan Ph.D.
WEBSITE	sonnetbio.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Sonnet BioTherapeutics Holdings Inc Frequently Asked Questions

What is the ticker symbol for Sonnet BioTherapeutics Holdings Inc? What does SONN stand for in stocks?

SONN is the stock ticker symbol of Sonnet BioTherapeutics Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sonnet BioTherapeutics Holdings Inc (SONN)?

As of Fri May 17 2024, market cap of Sonnet BioTherapeutics Holdings Inc is 5.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SONN stock?

You can check SONN's fair value in chart for subscribers.

What is the fair value of SONN stock?

You can check SONN's fair value in chart for subscribers. The fair value of Sonnet BioTherapeutics Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sonnet BioTherapeutics Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SONN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sonnet BioTherapeutics Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether SONN is over valued or under valued. Whether Sonnet BioTherapeutics Holdings Inc is cheap or expensive depends on the assumptions which impact Sonnet BioTherapeutics Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SONN.

What is Sonnet BioTherapeutics Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SONN's PE ratio (Price to Earnings) is -0.67 and Price to Sales (PS) ratio is 61.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SONN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sonnet BioTherapeutics Holdings Inc's stock?

In the past 10 years, Sonnet BioTherapeutics Holdings Inc has provided -0.767 (multiply by 100 for percentage) rate of return.